Cordyceps Militaris Trial Protocol for COPD Lung Function Decline

A 160-patient clinical trial protocol evaluates Cordyceps militaris capsules versus placebo for preserving lung function in mild-to-moderate COPD. The multi-center, double-blind study randomizes participants for a 24-week treatment period followed by a 24-week follow-up. Primary and secondary outcomes include post-bronchodilator FEV1 change, other lung function parameters, and patient-reported measures.

Use Cases

• Analyze clinical trial design and methodology for herbal interventions based on the described protocol.
• Study outcome measures for COPD clinical trials based on the listed primary and secondary endpoints.
• Benchmark patient-reported outcome measures in respiratory studies based on the CAT, CASA-Q, EQ-5D-5L, and mMRC scales mentioned.

Strengths

• The protocol is registered with a specific identifier (ChiCTR2400086743) on a clinical trial registry.
• The study design is explicitly detailed as a multi-center, randomized, double-blind, placebo-controlled trial involving 160 patients.

Limitations

• The dataset is a 55.9 KB DOCX file containing a study protocol, not structured patient-level data.
• Column-level documentation is absent; field semantics must be inferred from the textual description.
• Row count is unknown, which may limit suitability assessment for data analysis.

Provenance

Source

figshare

Collection Method

Uploaded as a study protocol document.

Freshness

Last updated 2026-05-25 06:07:17; freshness should be verified.